Approved and pipeline incretin drugs: liraglutide, dulaglutide, exenatide, orforglipron, amylin analogs like cagrilintide, and GLP-1/glucagon dual agonists.
Victoza · Saxenda · Xultophy (with insulin degludec) · NN2211
GLP-1 receptor agonist (once daily)
Novo Nordisk's once-daily GLP-1 drug, approved since 2010 for diabetes and 2014 for weight management. Generic versions became available from 2024.
Read moreFoundayo · LY3502970 · Orforglipron calcium
Oral small-molecule GLP-1 receptor agonist (not a peptide)
Lilly's once-daily GLP-1 pill, approved in April 2026 for weight management. It produced about 11% weight loss at the top dose and can be taken with or without food.
Read moreCagriSema (with semaglutide) · NN9838
Long-acting amylin analog (amylin and calcitonin receptor agonist)
Novo Nordisk's long-acting amylin analog, combined with semaglutide as CagriSema. CagriSema produced about 20% weight loss and awaits an FDA decision.
Read moreTrulicity · LY2189265
GLP-1 receptor agonist (Fc fusion protein, once weekly)
Eli Lilly's once-weekly GLP-1 drug for type 2 diabetes, approved in 2014. It lowered heart attack and stroke risk in the REWIND trial.
Read moreByetta (discontinued in the US) · Bydureon BCise (discontinued in the US) · Exendin-4 · AC2993
GLP-1 receptor agonist (exendin-4 analog)
The first GLP-1 drug, based on a peptide from Gila monster venom and approved in 2005. Brand-name Byetta and Bydureon were discontinued in the US in 2024.
Read moreBI 456906
GLP-1 and glucagon receptor dual agonist
Boehringer Ingelheim's weekly GLP-1 and glucagon dual agonist. Phase 3 trials showed 12 to 13% weight loss and large drops in liver fat; not yet approved.
Read moreXinermei (China) · LY3305677 · IBI362
GLP-1 and glucagon receptor dual agonist
A weekly GLP-1 and glucagon dual agonist approved in China in 2025 for weight management and type 2 diabetes. Not approved in the US.
Read moreALT-801
GLP-1 and glucagon receptor dual agonist (balanced 1:1)
Altimmune's weekly GLP-1 and glucagon dual agonist, focused on fatty liver disease. It has FDA Breakthrough designation for MASH and entered phase 3 in 2026.
Read moreSymlin (discontinued in the US) · Pramlintide acetate · Amylin analog
Amylin analog (amylinomimetic)
The first amylin-based drug, approved in 2005 as an add-on to mealtime insulin. It modestly lowered blood sugar and weight but is now discontinued in the US.
Read more
CagriSema combines cagrilintide and semaglutide in one weekly shot. Trial results (20.4% weight loss), side effects, the tirzepatide comparison and FDA status.
Contrave cost in 2026: $99 a month through the CurAccess program, $0 to $199 with the savings card, Medicare rules, and how its price compares with GLP-1 drugs.
Foundayo cost in 2026: $649 list price, LillyDirect self-pay from $149, the $25 savings card for insured patients and the $50 Medicare GLP-1 Bridge.
Trulicity cost with Medicare in 2026: how Part D covers it, the $615 deductible and $2,100 cap, Extra Help, Lilly Cares and Trulicity's 2028 negotiated price.
Trulicity cost without insurance in 2026: the $987 list price, why the $25 savings card needs coverage, Lilly Cares, LillyDirect and cheaper options.
Saxenda coupon guide for 2026: savings card terms ($25 or up to $200 off), who qualifies, generic liraglutide savings and the 2027 discontinuation.
Saxenda cost in 2026: the $1,349 list price, savings card, generic liraglutide, insurance and Medicare rules, and what Saxenda's 2027 discontinuation means.
Survodutide vs tirzepatide: glucagon vs GIP dual agonists compared on phase 3 weight loss, MASH liver data, side effects, approval status and cost in 2026.
Cagrilintide dosage in trials: 0.3 to 4.5 mg weekly alone, and 2.4 mg in CagriSema after a 16-week titration. What each dose did and why none is approved.
Cagrilintide with retatrutide or tirzepatide has not been tested in people. Only CagriSema (with semaglutide) has trial data. What a 2026 rat study found.
Foundayo vs Wegovy pill: label doses, food rules, weight loss in each trial, side effects, interactions and who each daily GLP-1 pill may suit better.
Foundayo dose guide from the FDA label: 0.8 mg start, monthly steps to 5.5 mg, optional 9, 14.5 and 17.2 mg, missed doses, interactions and side effects.
Orforglipron vs tirzepatide: Foundayo pill (11.2% weight loss in ATTAIN-1) vs Zepbound shot (20.9% in SURMOUNT-1). Dosing, side effects, diabetes data, cost.
Dulaglutide vs semaglutide: in SUSTAIN 7, Ozempic cut HbA1c and weight more than Trulicity. Doses, heart outcomes, side effects and Trulicity for weight loss.
Liraglutide vs semaglutide: in STEP 8, Wegovy gave 15.8% weight loss vs 6.4% on Saxenda. Daily vs weekly dosing, side effects, generics and cost compared.
The best peptides for weight loss ranked by evidence: approved semaglutide and tirzepatide, pills, late-stage retatrutide and CagriSema, and unproven AOD-9604.
AOD-9604 vs semaglutide: a growth hormone fragment that failed its obesity trial vs an approved GLP-1 with 15% weight loss. Evidence, safety and legality.
GLP-1 drugs compared for 2026: Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo, Saxenda and Trulicity side by side on approvals, dosing, results and prices.
Cagrilintide side effects in trials: nausea in 20% to 47% on the drug alone, stomach effects in 79.6% on CagriSema, injection-site reactions and who stopped.
CagriSema vs Zepbound: in REDEFINE 4, tirzepatide beat CagriSema (23.6% vs 20.2% weight loss). How they work, side effects, cost and FDA status in 2026.
FDA updates and new research, explained in 5 minutes. Every week, free.
Enter your email to get The Beginner's Guide to Peptides, a free 10-page PDF: what peptides are, why everyone's talking about them, the popular names, and how to read quality documents like a COA.
Download the guide (PDF)